drugset / Trial / NCT00259077

Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

NCT00259077

Phase 3 Completed 270 enrolled AstraZeneca Tanabe Pharma Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.

Timeline

Start
2003-10
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Omeprazole Other / unclassified 10 mg
Subject Omeprazole Other / unclassified 20 mg